CTLA4 and neoplasm: Taken together, these data suggest that chronic HS treatment upregulated TGFβ-mediated immune exhaustion, leading to tumor progression, and the combination of immune checkpoint inhibitor therapy (anti-CTLA4 mAb) with anti-TGFβ mAb is more efficient at reducing tumor progression.